GNI  Group Ltd. Logo

GNI Group Ltd.

Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.

2160 | T

Overview

Corporate Details

ISIN(s):
JP3386370005
LEI:
Country:
Japan
Address:
中央区日本橋本町二丁目2番2号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GNI Group Ltd. is a multinational, vertically integrated biopharmaceutical company engaged in the research, clinical development, manufacturing, and commercialization of pharmaceutical drugs and medical devices. The company focuses on developing novel treatments for intractable conditions with unmet medical needs, particularly in the areas of cancer and inflammatory diseases. With core operations spanning Japan, China, and the US, GNI Group leverages genetic analysis technology in its drug discovery pipeline. Its key commercial products include Etuary (pirfenidone) for the treatment of idiopathic pulmonary fibrosis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 10:05
Report Publication Announcement
確認書
Japanese 10.0 KB
2025-08-14 09:30
Interim Report
半期報告書-第25期(2025/01/01-2025/12/31)
Japanese 296.9 KB
2025-07-25 04:00
Share Issue/Capital Change
訂正臨時報告書
Japanese 28.9 KB
2025-07-24 10:09
Regulatory News Service
訂正臨時報告書
Japanese 40.7 KB
2025-04-23 09:00
Share Issue/Capital Change
臨時報告書
Japanese 32.7 KB
2025-03-31 09:00
Registration Form
確認書
Japanese 8.2 KB
2025-03-31 09:00
Governance Information
内部統制報告書-第24期(2024/01/01-2024/12/31)
Japanese 22.2 KB
2025-03-31 09:00
Annual Report
有価証券報告書-第24期(2024/01/01-2024/12/31)
Japanese 1.2 MB
2025-03-28 03:30
Post-Annual General Meeting Information
臨時報告書
Japanese 21.6 KB
2024-08-14 10:08
Regulatory News Service
臨時報告書
Japanese 19.0 KB
2024-08-14 09:26
Interim Report
半期報告書-第24期(2024/01/01-2024/12/31)
Japanese 301.9 KB
2024-08-14 09:26
Report Publication Announcement
確認書
Japanese 10.0 KB
2024-07-02 08:00
Major Shareholding Notification
訂正報告書(大量保有報告書・変更報告書)
Japanese 51.9 KB
2024-06-28 09:00
Major Shareholding Notification
大量保有報告書
Japanese 52.6 KB
2024-05-30 09:30
Share Issue/Capital Change
臨時報告書
Japanese 32.3 KB

Automate Your Workflow. Get a real-time feed of all GNI Group Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GNI Group Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GNI Group Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America
ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom
ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.